Swiss drug giant Roche (NASDAQOTH: RHHBY )
has continued a reasonable run of performance in the stock market. The
Swiss-listed shares have delivered middle-of-the-road performance this
year relative to other Big Pharma names like Lilly, Merck (NYSE: MRK ) , Bristol-Myers (NYSE: BMY ) , and Pfizer
and still offers a solid dividend. Roche continues to sport one of the
strongest oncology pipelines in the space, but the company also has the
opportunity to drive upside from its non-oncology pipeline, an area that
hasn't generated as much value in recent years.
Read more here:
Keep Calm and Carry On, Roche Stock
No comments:
Post a Comment